Brokerages Expect Aptevo Therapeutics Inc (APVO) Will Announce Quarterly Sales of $7.18 Million
Equities research analysts forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will report $7.18 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aptevo Therapeutics’ earnings. The highest sales estimate is $7.50 million and the lowest is $6.86 million. Aptevo Therapeutics posted sales of $6.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 5.1%. The firm is scheduled to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that Aptevo Therapeutics will report full year sales of $29.02 million for the current fiscal year, with estimates ranging from $28.02 million to $30.02 million. For the next financial year, analysts forecast that the company will report sales of $35.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Aptevo Therapeutics.
Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.44). The firm had revenue of $7.02 million during the quarter, compared to analysts’ expectations of $6.30 million. Aptevo Therapeutics had a negative return on equity of 119.17% and a negative net margin of 199.25%.
APVO stock traded down $0.03 during midday trading on Friday, hitting $0.75. 6,565 shares of the stock were exchanged, compared to its average volume of 549,952. The stock has a market cap of $33.57 million, a PE ratio of -0.32 and a beta of 2.64. Aptevo Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $6.35. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.66 and a current ratio of 2.76.
Several large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in Aptevo Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after purchasing an additional 16,482 shares during the period. Renaissance Technologies LLC lifted its position in Aptevo Therapeutics by 11.1% in the third quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock worth $6,488,000 after purchasing an additional 127,700 shares during the period. Acadian Asset Management LLC lifted its position in Aptevo Therapeutics by 4.8% in the fourth quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock worth $587,000 after purchasing an additional 21,059 shares during the period. Deutsche Bank AG lifted its position in Aptevo Therapeutics by 251.7% in the fourth quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after purchasing an additional 236,300 shares during the period. Finally, Clifford Swan Investment Counsel LLC acquired a new stake in Aptevo Therapeutics in the fourth quarter worth approximately $35,000. 17.08% of the stock is owned by institutional investors.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Recommended Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.